Even though the data on the expression of PD-1/PD-L1 in GBM patients are largely correlative based upon immunohistochemical (IHC) antibody staining or data mining from TCGA [119–123], late-phase clinical trials testing ICI in randomized clinical trials in unselected recurrent GBM patients did not meet the primary endpoint of improved overall survival [124]. Here, CD274 is linked to glioblastoma.